• 1
    Moser M, Mattingly TW. Critical evaluation of drug therapy of hypertension. Postgrad Med. 1955;17:351.
  • 2
    Moser M. The Treatment of Hypertension: A Story of Myths, Misconceptions, Controversies and Heroics. Darien , CT : Le Jacq Communications, Inc.; 2002.
  • 3
    Hypertension Detection and Follow-up Program Cooperative group. Five-year findings of the Hypertension Detection and Follow-up Program. I. Reduction in mortality of persons with high blood pressure, including mild hypertension. JAMA. 1979;242:25622571.
  • 4
    The sixth report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure. Arch Intern Med. 1997;157:24132446.
  • 5
    The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. JAMA. 2003;289:25602572.
  • 6
    Moser M, Black HR. The role of combination therapy in the management of hypertension. Am J Hypertens. 1998;11:73S78S.
  • 7
    Moser M, Prisant LM. Low-dose combination therapy in hypertension. Am Fam Physician. 1997;56(5):12751282.
  • 8
    Materson BJ, Reda DJ, Williams D. Lessons from combination therapy in Veterans Affairs Cooperative Study Group on antihypertensive agents. Am J Hypertens. 1996;9(12 pt 2):187S191S.
  • 9
    Moser M. Clinical Management of Hypertension. 6th ed. Caddo , OK : Professional Communications, Inc.; 2002.
  • 10
    Dahlof B, Devereux RB, Kjeldsen SE, et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet. 2002;359:9951003.
  • 11
    Lewis EJ, Hunsicker LG, Bain RP, et al. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. N Engl J Med. 1993;329:14561462.
  • 12
    Lewis EJ, Hunsicker LG, Clarke WR, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med. 2001;345:851860.
  • 13
    Brenner BM, Cooper ME, de Zeeuw D, et al.. Effects of Losartan on Renal and Cardiovascular Outcomes in Patients with Type 2 Diabetes and Nephropathy (RENAAL). N Engl J Med. 2001;345:861869.
  • 14
    PROGRESS Collaborative group. Randomized trial of a perindopril-based blood pressure-lowering regimen among 6105 individuals with previous stroke or transient ischemic attack. Lancet. 2001;358:10331041.
  • 15
    ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA. 2002;288:29812987.
  • 16
    Cushman WC, Ford CE, Cutler JA, et al. Success and predictors of blood pressure control in diverse North American Settings: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). J Clin Hypertens (Greenwich). 2002;4:393404.
  • 17
    Moser M, Pickering T, Sowers JR. Combination drug therapy in the management of hypertension: when, with what, and how? J Clin Hypertens (Greenwich). 2000;2:9498.
  • 18
    Wing LMH, Reifel CM, Ryan P, et al. A comparison of outcomes with angiotensin converting enzyme inhibitors and diuretics for hypertension in the elderly. Australian National Blood Pressure Study 2. N Engl J Med. 2003;348:583592.
  • 19
    Black HR, Elliott WJ, Grandits G, et al. Principal results of the Controlled Onset Verapamil Investigation of Cardiovascular Endpoints (CONVINCE) trial. JAMA. 2003;289:20732082.
  • 20
    Moser M. Suppositions and speculations-their possible effects on treatment decisions in the management of hypertension. Am Heart J. 1989;118:13621369.
  • 21
    Moser M. Why are physicians not prescribing diuretics more frequently in the management of hypertension? JAMA. 1998;179:18131816.
  • 22
    Moser M. Diuretics revisited-again. J Clin Hypertens (Greenwich). 2001;3:136138.
  • 23
    Frishman WH, Zawada ET, Smith LK, et al. Comparison of hydrochlorothiazide and sustained-release diltiazem for mild-tomoderate systemic hypertension. Am J Cardiol. 1987;59:615623.
  • 24
    Moser M. Approach to the treatment of blood pressure in the elderly and the octogenarian? Am J Geriatr Cardiol. 2000;9(suppl):1520, 24.
  • 25
    SHEP Cooperative group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension: final results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA. 1991;265:32553264.